Want to join the conversation?
Biopharma company $LXRX said the US FDA will need additional time to complete its review of the NDA for telotristat etiprate, an oral drug for treating carcinoid syndrome. In a notice received from the FDA, the PDUFA date for Priority Review of the drug has been extended by 3 months, from Nov. 30, 2016 to Feb. 28, 2017.
Can we see "Made in the USA" label on iPhones in the near future? Heard that $AAPL is considering the idea of manufacturing iPhone in America.
People who are looking for a steady growth stock should take a look at $EME. This stock has never had a significant downfall in the last five years. Comfortably beats consensus target most of the time. Such potential, much wow!
Looks like Creative Planning jumped on the bandwagon! Increased its stake by 91% in $EWBC. A lot of companies recently raised their stack too. I smell something’s cooking.
Hey $DIS, you are better off with Princess Cinderella and Prince Charming. Sports just ain’t your thing! Maybe it’s time you listened to investors about the ESPN separation!